AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03060538
Drug: BFKB8488A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously starting on Day 1 and according to dosing schedule.
Trial: NCT02228460
Drug: GZ/SAR402671
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Capsule; Route of administration: Oral
Trial: NCT04101461
Drug: Iron
RxNorm normalized name: Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PharaFerro27; Devart Lab Company, Egypt
Trial: NCT03859102
Drug: Intravenous Paracetamol intra-operatively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of Paracetamol intra-operatively, 1gram intravenous infusion.
Trial: NCT03859102
Drug: Infiltration of surgical wounds with local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infiltration of surgical wounds with local anaesthetic at the end of surgery, Bupivacaine 1-2mg/kg.
Trial: NCT03488147
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: resembling esomeprazole tablet
Trial: NCT03187106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo representing standard of care
Trial: NCT00841698
Drug: Paxil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Film-Coated Tablet
Trial: NCT04622956
Drug: Methotrexate Injectable Solution
RxNorm normalized name: methotrexate Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1:~* Level -1: Methotrexate 7.5 mg/m2 on D+6 and D+9\*. Level -1 will be explored only if the starting dose is too toxic (reduced dose).~* Level 0 \[Starting Dose\]: Methotrexate 10 mg/m2 on D+6 and 7.5 mg/m2 on D+9~* Level +1: Methotrexate 10 mg/m2 on D+6 and D+9~* Level +2: Methotrexate 15 mg/m2 on D+6 and 10 mg/m2 on D+9~Phase 2: dose determined in the phase 1 trial
Trial: NCT01100437
Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
Trial: NCT01100437
Drug: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
Trial: NCT04499443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This trial includes single-dose studies and multiple-dose studies, The single-dose study included six dose groups of 10 mg, 30 mg, 60 mg, 100 mg, 150 mg, 200 mg, 250mg and 300 mg. Based on the results of a single dose, select 1 to 3 doses to conduct multiple dose studies.
Trial: NCT01964014
Drug: advagrf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.~advagrf+sirolimus one time to eat.
Trial: NCT02258828
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT05363059
Drug: Hypoglycemic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: drug
Trial: NCT01003275
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two soft gels by mouth daily for 8 weeks
Trial: NCT00894556
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Rizatriptan
Trial: NCT02289950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously (IV) weekly
Trial: NCT00426621
Drug: Diclofenac Sodium Gel
RxNorm normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 grams per knee, 4 times per day, for 12 weeks
Trial: NCT00426621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 grams per knee, 4 times per day, for 12 weeks
Trial: NCT03932058
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all osteosarcoma patients will give regular chemotherapy for osteosarcoma, the protocol is the same as Methotrexate+Doxorubicin+Cisplatin.
Trial: NCT02528903
Drug: MHAB5553A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous administration, at various doses, depending on the cohort
Trial: NCT02528903
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose
Trial: NCT02175602
Drug: DCV 3DAA FDC
RxNorm normalized name: DYE FDC BLUE #1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination (daclatasvir \[DCV\] 30 milligrams, asunaprevir \[ASV\] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
Trial: NCT01043952
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
Trial: NCT00239382
Drug: Meloxicam ampoule
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00239382
Drug: Meloxicam tablet
RxNorm normalized name: Meloxicam Tablets
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03352362
Drug: ibuprofen (caldolor 10 mg / kg)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
Trial: NCT03352362
Drug: ibuprofen + propacetamol
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
Trial: NCT01067833
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, x28 days
Trial: NCT01218867
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
Trial: NCT04890418
Drug: Ketalar, 5 mg/mL Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will receive (slow intravenous injection) 0.3 mg/kg intravenous ketamine diluted by the pharmacy department into 10mL saline after the realization of PNB but before tourniquet set up and before start of surgery.
Trial: NCT03829657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, QD
Trial: NCT04194528
Drug: Oxycodone/acetaminophen 5/325 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is the Proteus digital medicine program consisting of a mobile application, a patch worn on the body, and oxycodone/acetaminophen 5/325 mg co-encapsulated with ingestible sensors. The duration of the intervention is 6 weeks.
Trial: NCT00271817
Drug: Comparator: ezetimibe/simvastatin + niacin (ER)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks
Trial: NCT00271817
Drug: Comparator: ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.
Trial: NCT00271817
Drug: Comparator: ezetimibe/simvastatin and niacin (ER)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks
Trial: NCT00271817
Drug: Comparator: ezetimibe and simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks
Trial: NCT01278095
Drug: GLPG0555 solid dispersion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solid dispersion capsules, 50 mg, single dose
Trial: NCT01278095
Drug: GLPG0555 nanosuspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanosuspension, 50 mg, single dose
Trial: NCT00834405
Drug: ARAVA® 20 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 20 mg, single-dose non-fasting
Trial: NCT03919526
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300mg/m2/d
Trial: NCT01632462
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks.
Trial: NCT00871247
Drug: Proscar® 5 mg Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
Trial: NCT03216473
Drug: Neuronox
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clostridium Botulinum Toxin A 100 U
Trial: NCT01425008
Drug: MLN2480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Escalation Phase: participants will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Participants may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. If it is determined that a participant would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Participants will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the participant discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a participant would derive benefit from continued therapy beyond 12 months.
Trial: NCT03503318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to TV-46000 will be administered per schedule specified in the arm.
Trial: NCT00954590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally three times daily
Trial: NCT00916253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):~* during 3 days at home~* during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo.
Trial: NCT00247897
Drug: Skin antisepsis
RxNorm normalized name: Skin antisepsis, oral cleansing, nasal antisepsis KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description
Trial: NCT04342221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01148537
Drug: Matching placebo transdermal patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
Trial: NCT03306732
Drug: Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * After anesthesia induction~* After separation from CPB~* On the evening of the day of surgery (22:00)~* On POD 1 twice a day at 8:00 and 22:00~* On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)~* On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)
Trial: NCT01353027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT03500900
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute administration of placebo tablet
Trial: NCT02403947
Drug: Suspension media
RxNorm normalized name: Stellaria media extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection suspension media
Trial: NCT01974544
Drug: Best medical treatment
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
Trial: NCT01974544
Drug: General interventions for all groups: blood presure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
Trial: NCT01974544
Drug: General interventions for all groups: dysilipidemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration \>4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (\>4.0 mmol/L).
Trial: NCT03751111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
Trial: NCT01389752
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04646759
Drug: Capecitabine combined with Pyrotinib
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000mg/m\^2 bid d1-d14，every 21 days Pyrotinib 400mg daily
Trial: NCT01319695
Drug: recombinant follicle stimulating hormone (FSH)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are \>18mm
Trial: NCT00881400
Drug: Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03072056
Drug: MIN-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01643135
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
Trial: NCT01604265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
Trial: NCT00455429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules to JNJ-26113100 (50 milligram \[mg\]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
Trial: NCT00455429
Drug: JNJ-26113100 (50 mg) once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
Trial: NCT03149081
Drug: Boswellia
RxNorm normalized name: boswellia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia is an extract from frankincense
Trial: NCT00455429
Drug: JNJ-26113100 (100 mg) once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
Trial: NCT00455429
Drug: JNJ-26113100 (100 mg) twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
Trial: NCT00455429
Drug: JNJ-26113100 (250 mg) twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
Trial: NCT04545060
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% NaCl) given by intravenous infusion (single dose)
Trial: NCT01832974
Drug: IL-13-PE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-13-PE intravenous infusion
Trial: NCT03341962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets manufactured to mimic IMU-838 tablets
Trial: NCT00239863
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03869528
Drug: 5 sprays of 10% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 sprays of 10% lignocaine
Trial: NCT03869528
Drug: 10 sprays of 10% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 sprays of 10% lignocaine
Trial: NCT04082754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride, same volume and same duration as CSL311
Trial: NCT01544946
Drug: placebo po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile water
Trial: NCT00800332
Drug: CYT003-QbG10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT00800332
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT01217814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Trial: NCT01880632
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given the perioperative chemotherapy as below once recruited:~Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）~Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:~Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1\~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
Trial: NCT01217814
Drug: methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: tablet or solution for injection~Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)
Trial: NCT01217814
Drug: Folic/folinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral Folic/folinic acid continued according to local standard.
Trial: NCT00963937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
Trial: NCT02433730
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT02433730
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular injection
Trial: NCT02298829
Drug: Subjects Previously Treated with AA4500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment to be administered - observational only
Trial: NCT02970292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken as two tablets, once daily by mouth